Confirmed
One controlled phase 3 trial met its main goal, and inebilizumab is approved for this use.
Inebilizumab: prevent attacks in NMOSD
NMOSD · Other B-cell / plasma-cell targeting
Two or more controlled phase 3 trials met their main goal, or one did and a medicine of this approach is approved for this use.
- Trials
- 5
- Running now
- 3
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 231
Deciding trials (phase 3): 1 met, 0 did not.
Other linked trials: 4
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
- A Double-masked, Placebo-controlled Study with Open label Period to Evaluate MEDI-551 in NMO/NMOSDdecides the statusMet main goal
Phase 2/3 · 2015 · Placebo-controlled · MSFT-NCT02200770
Other linked trials: 4
These linked trials do not set the status.
- BEST-NMOSDOngoing
Phase 4 · 2026 · Not randomised
Phase 4 · 2024 · Not randomised
- STARGlu-NMOOngoing
Phase 3 · 2025 · Not randomised
Phase not applicable · 2025 · Compared with inebilizumab
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-27First listed as Confirmed
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error